Literature DB >> 16982785

Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.

Florian M E Wagenlehner1, Martina Kinzig-Schippers, Uwe Tischmeyer, Christine Wagenlehner, Fritz Sörgel, Kurt G Naber.   

Abstract

Twelve volunteers received a single oral dose of 1,000 mg extended-release (XR) ciprofloxacin versus 500 mg levofloxacin to assess urinary bactericidal titers (UBTs) against common uropathogens. Areas under UBT-time curves were significantly larger for Proteus mirabilis with XR ciprofloxacin and for staphylococci with levofloxacin.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16982785      PMCID： PMC1635228          DOI： 10.1128/AAC.00477-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.

Authors:  Alison K Meagher; Alan Forrest; Axel Dalhoff; Heino Stass; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

2.  Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.

Authors:  G G Zhanel; I D Kirkpatrick; D J Hoban; A M Kabani; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

3.  Bacterial biofilms and catheters in experimental urinary tract infection.

Authors:  T Goto; Y Nakame; M Nishida; Y Ohi
Journal:  Int J Antimicrob Agents       Date:  1999-05       Impact factor: 5.283

4.  Rat model of experimental bacterial prostatitis.

Authors:  J C Nickel; M E Olson; J W Costerton
Journal:  Infection       Date:  1991       Impact factor: 3.553

5.  Antibiotic activity in microbiological media versus that in human urine: comparison of ampicillin, ciprofloxacin, and trimethoprim-sulfamethoxazole.

Authors:  G R Drobot; J A Karlowsky; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

6.  Biofilm formation among methicillin-resistant Staphylococcus aureus isolates from patients with urinary tract infection.

Authors:  Eiichi Ando; Koichi Monden; Ritsuko Mitsuhata; Reiko Kariyama; Hiromi Kumon
Journal:  Acta Med Okayama       Date:  2004-08       Impact factor: 0.892

Review 7.  Host subversion by formation of intracellular bacterial communities in the urinary tract.

Authors:  Gregory G Anderson; Steven M Martin; Scott J Hultgren
Journal:  Microbes Infect       Date:  2004-10       Impact factor: 2.700

8.  Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis.

Authors:  Sheryl S Justice; Chia Hung; Julie A Theriot; Daniel A Fletcher; Gregory G Anderson; Matthew J Footer; Scott J Hultgren
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-22       Impact factor: 11.205

9.  Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.

Authors:  Florian M E Wagenlehner; Stephan Wydra; Hajime Onda; Martina Kinzig-Schippers; Fritz Sörgel; Kurt G Naber
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

10.  Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers.

Authors:  K G Naber; U Theuretzbacher; M Kinzig; O Savov; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191
View more
  6 in total

1.  Ex Vivo Urinary Bactericidal Activity and Urinary Pharmacodynamics of Fosfomycin after Two Repeated Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Subjects.

Authors:  E Wenzler; K M Meyer; S C Bleasdale; M Sikka; R E Mendes; K L Bunnell; M Finnemeyer; S L Rosenkranz; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 2.  Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis.

Authors:  Florian M E Wagenlehner; Wolfgang Weidner; Kurt G Naber
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers.

Authors:  Florian M E Wagenlehner; Fabian Münch; Adrian Pilatz; Birte Bärmann; Wolfgang Weidner; Christine M Wagenlehner; Marion Straubinger; Holger Blenk; Wolfgang Pfister; Michael Kresken; Kurt G Naber
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

4.  Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin.

Authors:  Adam L Vanwert; Chutima Srimaroeng; Douglas H Sweet
Journal:  Mol Pharmacol       Date:  2008-04-01       Impact factor: 4.436

5.  Pharmacokinetic interaction of ciprofloxacin with diclofenac: a single-dose, two-period crossover study in healthy adult volunteers.

Authors:  Zafar Iqbal; Abbas Khan; Attiqa Naz; Jamshaid A Khan; Ghulam S Khan
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

6.  Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.

Authors:  A Dalhoff; S Schubert; A Vente
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.